A double-blind, placebo-controlled, parallel group multicenter study to assess the safety, tolerance and efficacy of a single subcutaneous dose of tezampanel in patients with acute migraine.

Trial Profile

A double-blind, placebo-controlled, parallel group multicenter study to assess the safety, tolerance and efficacy of a single subcutaneous dose of tezampanel in patients with acute migraine.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Tezampanel (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Raptor Pharmaceutical Corp
  • Most Recent Events

    • 30 Jun 2008 Primary endpoint met, according to interim results presented at the 50th Annual Scientific Meeting of the American Headache Society, as reported in a TorreyPines media release (9090616).
    • 13 May 2008 Results will be presented at the 2008 AHS Scientific Meeting, according to a TorreyPines media release.
    • 22 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top